Objectives: The oxazolidinone-resistant Enterococcus faecalis E349 from a human patient tested negative for the cfr gene and 23S rRNA mutations. Here we report the identification of a novel oxazolidinone resistance gene, optrA, and a first investigation of the extent to which this gene was present in E. faecalis and Enterococcus faecium from humans and food-producing animals.
Introduction
Enterococcal infections have become one of the most challenging nosocomial problems, with two species, Enterococcus faecium and Enterococcus faecalis, ranking among the leading causes of hospital-acquired infections. 1, 2 The ability of enterococci to acquire and exchange plasmids and transposons that carry antimicrobial resistance and virulence genes has contributed to their role as multiresistant pathogens. 3 The emergence and rapid spread of VRE represents a particular challenge, as there are few remaining options for antimicrobial treatment of infections caused by VRE. 4, 5 Linezolid, the first oxazolidinone introduced into clinical use in the USA in 2000 and in China in 2007, is a most promising agent against infections caused by VRE, MRSA and penicillin-resistant pneumococci. 6 However, oxazolidinone resistance among enterococci has been reported during recent years. Mutations in the central loop of domain V of the 23S rRNA represented the most common mechanism of oxazolidinone resistance in enterococci, with G2576T (Escherichia coli numbering) as the predominantly found mutation. 5 In general, oxazolidinone resistance in enterococci conferred by mutations has commonly been associated with prolonged courses of linezolid administration, 7 and sporadic cases of nosocomial transmission of oxazolidinone-resistant enterococci between patients have been documented. 8, 9 Transferable oxazolidinone resistance due to the multiresistance gene cfr has been reported in enterococci of both human and animal origin. 10 The gene cfr encodes an rRNA methyltransferase that modifies the adenine residue at position 2503 in domain V of the 23S rRNA and thereby confers resistance to oxazolidinones, phenicols, lincosamides, pleuromutilins and streptogramin A (PhLOPS A ) antibiotics. 11 A novel oxazolidinone, tedizolid, was approved in June 2014 by the FDA for the management of acute bacterial skin and skin structure infections in adult humans. Tedizolid has increased activity against linezolid-resistant isolates that harbour the cfr gene, possibly due to the structural differences between these two oxazolidinones in the C5 substituents of the A ring. 12 In this study we report a novel gene, designated optrA, which confers transferable resistance to oxazolidinones (linezolid and tedizolid) and phenicols (chloramphenicol and florfenicol) in E. faecalis and E. faecium isolates from humans and foodproducing animals.
Materials and methods

Bacterial isolates
Initially, three oxazolidinone-resistant E. faecalis isolates, E349, E363 and E399, of human origin were collected in 2009 from Tianjin Medical University General Hospital, which participated in the Ministry of Health National Antimicrobial Resistance Investigation Net programme in China. To screen a larger collection of Enterococcus isolates for the presence of the novel oxazolidinone resistance gene, 595 clinical non-duplicate Enterococcus spp. isolates (E. faecalis n ¼ 236; E. faecium n ¼ 359) were collected from the Second Affiliated Hospital of Zhejiang University (SAHZU) during 1998 -2014 in Hangzhou, China (Table S1 , available as Supplementary data at JAC Online). In addition, 290 non-duplicate Enterococcus spp. isolates (E. faecalis n ¼202; E. faecium n¼88) of animal origin, including 149 isolates from porcine faecal samples and 141 isolates from cloacal swabs of chickens, were collected during 2009 -13 from farms and abattoirs in five provinces/cities, including Shandong, Henan, Tibet, Guangdong and Shanghai (Table S2 ). The vancomycin-resistant E. faecium A4 was selected from the SAHZU collection for mating assays.
Bacterial species identification and molecular typing
Species identification of enterococci of human and animal origin was conducted by 16S rDNA sequencing and MALDI-TOF MS (BrukerDaltonik GmbH, Bremen, Germany). PCR-directed detection of the cfr gene and 23S rRNA mutations was performed following previously described procedures. 13, 14 Isolates exhibiting oxazolidinone resistance, but negative for cfr and 23S rRNA mutations, were genotyped by PFGE and MLST, as described previously. 13 Since the clinical E. faecalis isolates E349, E363 and E399 exhibited an indistinguishable PFGE pattern ( Figure S1 ), only isolate E349 was selected for further analysis.
Plasmid analysis, transfer and cloning experiments
The plasmids of E. faecalis E349 were extracted using the Qiagen Plasmid Midi Kit (Qiagen, Germany) and transferred into E. faecalis JH2-2 via electrotransformation. The transferability of resistance to linezolid was also assessed by filter mating using E. faecalis E349 as donor and E. faecalis FA2-2 and the vancomycin-resistant E. faecium A4 as recipients. Both the transformants and transconjugants were selected on brain heart infusion (BHI) plates containing 3 mg/L linezolid and 25 mg/L rifampicin. The approximate size of the transferred plasmid was estimated by S1 nuclease PFGE. 13 The conjugation frequency was determined as described previously. 15 The plasmid of the transformants was extracted and then subjected to whole-plasmid sequencing by constructing a shotgun library using Illumina Hiseq 2500, which produced 100 bp paired-end reads (Berry Genomics Company, Beijing, China). A draft assembly of the plasmid was conducted using CLC Genomics Workbench 5 (CLC Bio, Aarhus, Denmark), which produced six contigs that had average coverage of .1000-fold. Gap closure of the plasmid was done by PCR using a modified random primer walking strategy. 13 Sequence analysis was conducted using ORF Finder (http://www.ncbi.nlm.nih.gov/gorf/gorf.html) and the BLAST functions (http://blast.ncbi.nlm.nih.gov/Blast.cgi).
To confirm the role of the gene in question in oxazolidinone resistance, a 2582 bp DNA segment was amplified using primers opR-F (5 ′ -GCTCTA GATTTCTCACCCAGATATGCC-3 ′ ) and opR-R (5 ′ -CGGGATCCCGGCAAACTCAA AAGGTC-3 ′ ). This segment included the putative oxazolidinone resistance gene, as well as 491 bp of its upstream region and 123 bp of its downstream region. The amplicon was inserted into the shuttle plasmid pAM401 and then transferred into E. faecalis JH2-2 and Staphylococcus aureus RN4220 by electrotransformation. Transformants were selected on BHI plates containing 2 mg/L linezolid.
Antimicrobial susceptibility testing
The MICs for all original isolates, transconjugants and transformants were determined by broth microdilution following the recommendations given in CLSI documents VET01-S2 and M100-S25. 16 ,17 E. faecalis ATCC 29212 served as a quality control strain. An internal PCR was designed to detect the optrA gene among Enterococcus isolates from humans and animals using the primers A-F (5 ′ -AGGTGGTCAGCGAACTAA-3 ′ ) and A-R (5 ′ -ATCA ACTGTTCCCATTCA-3 ′ ). The size of the expected PCR product was 1395 bp. All isolates carrying the gene in question were investigated for their MICs of chloramphenicol, florfenicol, linezolid, tedizolid, vancomycin, gentamicin, ampicillin and daptomycin, as well as for their PFGE patterns and their MLST types. S1-PFGE and Southern blotting were conducted to confirm the location of the novel resistance gene in each of these isolates. 13 In addition, these isolates were analysed by PCR for the presence of the phenicol exporter genes fexA and fexB as described previously. 13 
Results
Characterization of the cfr-and 23S rRNA mutationnegative E. faecalis E349
Neither the cfr gene nor mutations in 23S rRNA were observed in E. faecalis E349. Both the transformant (designated JH2-2/pE349) and the transconjugant (designated FA2-2-E349) exhibited 4-to 8-fold increases in the MICs of linezolid and tedizolid, compared with recipient strains JH2-2 and FA2-2 (Table 1) . S1-PFGE revealed the presence of a plasmid of 36 kb, designated pE349, in both the original E349 and the transformant E. faecalis JH2-2/pE349 ( Figure 1a ). Oxazolidinone-resistant transconjugants were obtained with a frequency of 2.21×10
26 per donor cell, suggesting that pE349 is a conjugative plasmid. These results strongly suggested the existence of a novel plasmid-borne oxazolidinone resistance gene in E. faecalis E349.
Characterization of the plasmid pE349 and identification of the gene optrA
To identify this gene, plasmid pE349 obtained from E. faecalis JH2-2/pE349 was sequenced completely. It had a size of New mobile oxazolidinone and phenicol resistance gene optrA 36 331 bp (GenBank accession number KP399637). A total of 39 ORFs coding for proteins of .50 amino acids were identified ( Figure 2 and Table S3 ). When searching for the potential oxazolidinone resistance gene in pE349, a 1968 bp gene encoding a 655 amino acid protein that exhibited 99.4% (651/655 amino acids) identity to a putative ABC transporter from E. faecalis 599 (GenBank accession number EJU90935.1) and E. faecium C1904 (GenBank accession number EJY24646.1) was detected, both of which represent reference genomes for the Human Microbiome
Project. E. faecalis JH2-2, carrying plasmid pAM401 with the cloned ABC transporter gene, exhibited 16-, 8-and 4-fold increases in the MICs of florfenicol, linezolid and tedizolid, respectively, when compared with the MICs of E. faecalis JH2-2 carrying only the shuttle vector pAM401 (Table 1) , while no MIC changes were found for ciprofloxacin, erythromycin, tetracycline and amikacin (data not shown). In addition, S. aureus RN4220 carrying pAM401 with the cloned ABC transporter gene exhibited 16-fold, 4-fold and 4-fold increases in the MICs of florfenicol, linezolid and The shuttle vector pAM401 carries a pIP501-analogous cat gene that confers high-level resistance to chloramphenicol, but not to florfenicol.
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tedizolid, respectively, when compared with the MICs of S. aureus RN4220 carrying only pAM401 (Table 1) , while no MIC changes were found for clindamycin, valnemulin, virginiamycin M1 (data not shown) and chloramphenicol. The high chloramphenicol MICs of ≥128 mg/L (Table 1) , which did not change in the presence of optrA, were due to the presence of a pIP501-analogous cat gene that confers high-level resistance to chloramphenicol, but not to florfenicol. These results strongly suggested that the ABC transporter gene mediated combined resistance to oxazolidinones and phenicols in E. faecalis and S. aureus. Therefore, it was designated optrA (oxazolidinone phenicol transferable resistance). Detailed analysis of this ABC transporter revealed two ATP-binding domains, each containing the ABC family characteristic motifs, including the conserved ABC signature and the Walker A and Walker B motifs, but lacked transmembrane domains ( Figure S2 ). 18 A phylogenetic tree based on a multi-sequence alignment (http://www.pasteur.fr/recherche/unites/pmtg/abc/ advanced.html) indicated that OptrA clustered together with the proteins Vga(A), Vga(C), Vga(E) and Lsa(E), which confer resistance to lincosamides, pleuromutilins and streptogramin A antibiotics (Figure 3) .
Among the 39 ORFs identified in plasmid pE349, 21 encoded hypothetical proteins with no defined function, while the products of the remaining 18 exhibited divergent similarities (23%-99%) to proteins with known functions, including antimicrobial resistance (optrA and fexA), plasmid replication (repB and repC), plasmid maintenance (mazF and lysS) and conjugative transfer (mobA, prgI, traE, tnp and traG) ( Table S3 ). The average GC content of plasmid pE394 (34.4%) was in the range of that of the E. faecalis genomes (33.3% -37.5%) available in the GenBank database.
Transferability of pE349 into vancomycin-resistant E. faecium A4
Conjugation was not only successful using E. faecalis E349 (with pE349) as donor and the clinical vancomycin-resistant E. faecium A4 with the vanA-carrying plasmid pA4 as recipient, but also with E. faecium A4 as donor and E. faecalis E349 as recipient. Two transconjugants, designated E. faecium A4-E349 and E. faecalis E349-A4, respectively, were obtained. S1-PFGE and Southern blot analysis using probes for optrA and vanA revealed that the 60 kb vanA-carrying plasmid pA4 and the 36 kb optrA-carrying plasmid pE349 can co-exist (Figure 1b) and that resistance to oxazolidinones, phenicols and vancomycin is expressed in both transconjugants (Table 1) .
Screening for the presence of optrA among E. faecalis and E. faecium of human and animal origin Among the additional 885 Enterococcus spp. isolates (E. faecalis n¼ 438; E. faecium n¼ 447) examined in this study, 58 (E. faecalis n¼ 51; E. faecium n¼ 7) were positive for the optrA gene, including 12 (12/595, 2.0%) from humans and 46 (46/290, 15.9%) from animals (pigs n ¼ 37; chickens n ¼ 9). Among the 12 human Enterococcus spp., 10 were E. faecalis and 2 were E. faecium (Table S1 ). The 46 optrA-positive Enterococcus isolates from animals included 41 E. faecalis and 5 E. faecium (Table S2 ). The gene optrA was detected more frequently in isolates from pigs (37/149, 24.8%, E. faecalis n ¼ 33 and E. faecium n ¼ 4) than in those from chickens (9/141, 6.4%, E. faecalis n¼ 8 and E. faecium n¼ 1). All 58 optrA-positive isolates from the screening study and the three initial E. faecalis isolates of human origin from Tianjin were subjected to PFGE analysis. Using a cut-off at 80% pattern similarity, the 54 E. faecalis and 7 E. faecium clustered into 28 and 7 PFGE subtypes, respectively ( Figures S1 and S3) . Isolates of the same source that exhibited indistinguishable PFGE patterns were considered as duplicate isolates. All 15 human isolates and 25 non-duplicate isolates of animal origin (in total 33 E. faecalis and 7 E. faecium) were further analysed by MLST, localization of the optrA gene, detection of phenicol exporter genes and antimicrobial susceptibility testing ( Table 2 ). The optrA gene was located on plasmids in 16 E. faecalis isolates, in the chromosomal DNA of 17 isolates (E. faecalis n¼ 14; E. faecium n¼ 3) or on both a plasmid and chromosomal DNA in 7 isolates (E. faecalis n ¼ 3; E. faecium n¼ 4; Figure S4) . Six E. faecalis of animal origin belonged to six different STs (ST27, ST116, ST256, ST476, ST480 and ST593), all of which were shared by 10 human isolates (Table 2 and Figure 4) . Moreover, the human E. faecalis isolate E347 from Ningbo and the porcine isolate 23-1 from Guangdong were in the same PFGE cluster (subtypes R1 and R2) and shared the same MLST profile ST593 (Table 2 and Figure 4) . A similar observation was made for the human E. faecalis isolate E381 from Taizhou and the porcine isolate XY12 from Henan, which also clustered together by PFGE (Y1 and Y2) and MLST (ST256) ( Table 2 and Figure 4 ).
Discussion
So far, the gene cfr has been the only transferable oxazolidinone resistance gene in enterococci. 10 The genes cfr and optrA differ in their mechanisms of resistance and in their substrate spectrum. While cfr codes for a 23S rRNA methyltransferase that confers resistance to PhLOPS A antibiotics, 11 optrA codes for an ABC transporter that confers resistance to oxazolidinones and phenicols. Besides these differences, the two genes are often located on plasmids, which might also harbour additional resistance Figure 3 . Phylogenetic analysis of OptrA and other ABC transporters involved in antimicrobial resistance. The phylogenetic tree was generated using the maximum likelihood method. The GenBank accession numbers of proteins are indicated. Numbers next to the branching points indicate the relative support from 500 replications. Analysis was performed using the MEGA 6.0.6 software package (Tempe, AZ, USA). 
Continued
New mobile oxazolidinone and phenicol resistance gene optrA genes. 10 This fact is of particular relevance when considering the dissemination of optrA-carrying plasmids under the selective pressure imposed by the use of antimicrobial agents other than oxazolidinones and phenicols. Moreover, both genes proved to be functionally active not only in Enterococcus spp., but also in S. aureus. The observation that in vitro transfer experiments resulted in transformants and transconjugants, in which the optrA-carrying plasmid was stably maintained and in which the optrA gene was functionally expressed, point to the likelihood of in vivo transfer of optrA-carrying plasmids between different enterococcal species, but also between enterococci and other Gram-positive bacteria, such as staphylococci. Examples of resistance gene flux between enterococci and staphylococci are the Tn916-borne tetracycline resistance gene tet(M), 19 the Tn917/ Tn551-borne macrolide-lincosamide-streptogramin B resistance gene erm(B), 20 the Tn1546-borne vanA gene cluster for glycopeptide resistance 21 and, most recently, the transfer of a multiresistance gene cluster carrying the resistance genes aadE (streptomycin resistance), spw (spectinomycin resistance), lsa(E) (resistance to pleuromutilins, lincosamides and streptogramin A) and lnu(B) (lincosamide resistance). 22 -25 The OptrA protein exhibited .99% identity to putative ABC transporters from enterococci of human origin. However, it is not known whether the enterococci that carry these optrA-related genes are resistant to oxazolidinones and phenicols. If not, the few amino acid substitutions observed between OptrA and the aforementioned ABC transporters might account for a different substrate specificity.
One important question refers to the potential role of foodproducing animals in the epidemiology of human E. faecalis and E. faecium carrying the optrA gene. Although the data presented in this study do not provide direct evidence for the transmission of optrA-positive isolates between animals and humans, the finding of E. faecalis isolates from humans and pigs with similar PFGE patterns and the same MLST profile points to an exchange of such isolates. However, the direction of exchange remains to be clarified. For E. faecium, the majority of the optrA-positive isolates from humans, pigs and chickens belonged to CC17, a distinct high-risk clonal complex, which was found to be associated with the majority of hospital outbreaks and clinical infections in five continents. 26 A recent review suggested that E. faecium isolates of animal origin might not constitute a human health hazard, but could act as donors of antimicrobial resistance genes for other pathogenic enterococci. 27 In contrast, E. faecalis of animal origin seemed to be a human health hazard, as the same types of E. faecalis could be detected in samples from animals, meat, faecal samples from humans in the community and patients with bloodstream infections. 27 The observation that the optrA-carrying plasmid pE349 could easily be transferred between E. faecalis and E. faecium via conjugation and that it could stably replicate and express its resistance genes in the presence of a plasmid that carried the vanA gene cluster is alarming. Such transfer eventswhen occurring in vivo-might seriously limit the therapeutic options for infections caused by VRE.
The first optrA-carrying E. faecium isolate of human origin was detected in 2005. This happened 2 years before linezolid, the sole commercially available oxazolidinone in China, was approved for use in human medicine in 2007. Moreover, all 15 patients from whom optrA-positive E. faecalis or E. faecium was isolated did not receive linezolid or chloramphenicol, both of which could directly select for the optrA gene. Linezolid has not been approved for Wang et al.
veterinary applications worldwide, while florfenicol-approved in 1999-is widely used in food-producing animals. Since the banning of chloramphenicol from use in food-producing animals in China in 2002, florfenicol appears to be the only antimicrobial agent that directly selects for optrA in isolates of food animal origin. The observation that the optrA gene was more frequently detected in enterococci of animal origin (15.9%) than in enterococci of human origin (2.0%) might suggest an animal reservoir. However, another scenario could be that the optrA gene might have developed in human enterococci and-after transfer to animal enterococci-has disseminated more rapidly in enterococci of animal origin, possibly under the selective pressure imposed by the use of florfenicol. In China, florfenicol-containing antimicrobial agents are available for the treatment of enteric, respiratory tract or uterine infections in swine, cattle or poultry. When excreted, florfenicol remained bioactive in soils and might exert a selective pressure on bacteria in the environment. 28 This selective pressure might support the evolution of novel genes that confer resistance to florfenicol (and possibly also to other antimicrobial agents). 29 Bearing in mind that antimicrobial agents such as florfenicol can select for genes, such as cfr and optrA, that also confer resistance to critically important antimicrobial agents in human medicine, such as the oxazolidinones linezolid and tedizolid, 30 the prudent use of florfenicol in food-producing animals is urgently warranted. The same applies to the use of antimicrobial agents of last resort, such as linezolid and tedizolid, in human medicine.
